Myelodysplastic Syndrome (MDS) Drugs Market Research Report - Global Forecast till 2027

Global Myelodysplastic Syndrome (MDS) Drugs Market Research Report: Information by Drug Type (Chemotherapy, Immunomodulatory Drugs), Type of Syndrome (Refractory Cytopenia with Multilineage Dysplasia, Refractory Anemia, Refractory Anemia with Excess Blasts, Refractory Anemia with Ringed Sideroblasts, Refractory Cytopenia with Multilineage Dysplasia), Route of Administration (Oral, Parenteral), End-User (Hospitals, Clinics, Ambulatory Surgical Centers) and Region - Global Forecast till 2027

ID: MRFR/HC/6662-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Scenario


The global myelodysplastic syndrome (MDS) drugs market is expected to grow significantly over the forecast period. It is anticipated that the market held a value of USD 1,581.59 million in 2018 and is projected to register a CAGR of 10.1% over the forecast period.


The increasing participation of key players is one of the key factors driving the Myelodysplastic Syndrome (MDS) drugs market. In 2018, the US Food and Drug Administration approved a generic injectable product, decitabine for Lupin Ltd. There are various other MDS medications available in the market.


Various other factors such as the promotion of clinical studies related to MS, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drug manufacturers are boosting the market growth.


However, the risk of infections during blood transfusions and side-effects of chemotherapy may hamper market growth over the forecast period.


Segmentation


The global myelodysplastic syndrome (MDS) drugs market is segmented based on type, type of syndrome, route of administration, end user, and region.


Based on type, the global myelodysplastic syndrome (MDS) drugs market is further segmented into chemotherapy, immunomodulatory drugs, and others. The chemotherapy segment is sub-segmented as conventional drugs and hypomethylating drugs. Hypomethylating drugs include Azacitidine and Decitabine. Conventional drugs comprise Cytarabine, Daunorubicin, and Idarubicin.


Based on the type of syndrome, the MDS drugs market at the global level is segmented into refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts,  refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and others.


Based on the route of administration, the market is segmented into oral, parenteral, and others.


Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others.


The segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


The myelodysplastic syndrome (MDS) drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European Myelodysplastic Syndrome (MDS) drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Myelodysplastic Syndrome (MDS) drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The myelodysplastic syndrome drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key Players



  • BluePoint Laboratories

  • Celgene Corporation

  • Celgene Europe Limited

  • Reddy's Laboratories, Inc.

  • Johnson & Johnson

  • Lupin Ltd Corporation

  • Otsuka America Pharmaceutical Inc.

  • Sandoz

  • Shilpa Medicare Limited

  • Sun Pharmaceutical Industries Inc.


Regional Market Summary


Global Myelodysplastic Syndrome (MDS) Drugs Market Share (%), by Region, 2018  Myelodysplastic Syndrome (MDS) Drugs Market


Sources: MRFR Analysis


The Americas dominated the global MDS drugs market, owing to the increasing number of patients detected with MDS yearly. According to the statistics published by the American Society of Clinical Oncology in 2019, around 10,000 patients are detected with MDS in the US yearly.


In the European region, various studies have been performed to study the prevalence of MDS across different age groups. For instance, the National Institutes of Health conducted a successive study among children with MDS for 15 years. Under the study, 426 children were investigated for Germline GATA-2 mutations and primary MDS. The studies revealed that Germline GATA-2 mutations highly prevailed in patients with monosomy 7 type of mutation. Thus, the European region has a potential scope for the MDS drugs market.


Asia-Pacific is expected to grow owing to the rising research and development activities in this region.  The study of clinical features is very important before proceeding for treatment methodology for a patient. As per the study published in the Leukemia Journal in 2018, the difference in clinical features among the Japanese and Caucasian patients with myelodysplastic syndromes was noticed. The study revealed that; chronic lymphocytic leukemia is more frequent in the Caucasians population than the Japanese population. This could be due to susceptibility specific location of the genome. Thus, the MDS drugs market in APAC is predicted to gain the third-largest market share.


The Middle East and Africa held the least share in the global myelodysplastic syndrome (MDS) drugs market due to low economic development, especially within the African region.


Intended Audience



  • Pharmaceutical companies

  • Government and private laboratories

  • Research and development (R&D) companies

  • Research laboratories

  • Market research and consulting service providers


Market Segmentation


Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type



  • Chemotherapy

  • Hypomethylating Drugs

    • Azacitidine

    • Decitabine

    • Conventional drugs

    • Cytarabine



  • Daunorubicin

    • Idarubicin

    • Immunomodulatory Drugs



  • Lenalidomide

    • Thalidomide

    • Others




Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type of Syndrome



  • Refractory Anemia

  • Refractory Anemia with Ringed Sideroblasts

  • Refractory Anemia with Excess Blasts

  • Refractory Cytopenia with Multilineage Dysplasia

  • Others


Global Myelodysplastic Syndrome (MDS) Drugs Market, by Route of Administration



  • Oral

  • Parenteral

  • Others


Global Myelodysplastic Syndrome (MDS) Drugs Market, by End User



  • Hospitals

  • Clinics

  • Ambulatory Surgical Centers

  • Others



Report Scope:
Report Attribute/Metric Details
  Market Size   2025: Significant Value
  CAGR   10.1% (2019-2025)
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Type, Type of Syndrome, End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   BluePoint Laboratories, Celgene Corporation, Celgene Europe Limited, Dr. Reddy's Laboratories Inc., Johnson & Johnson, Lupin Ltd Corporation, Otsuka America Pharmaceutical Inc, Sandoz, Shilpa Medicare Limited, Sun Pharmaceutical Industries Inc
  Key Market Opportunities   The increasing participation of key players is one of the key factors
  Key Market Drivers

  • Increasing Geriatric Population.
  • rise in regulatory approvals.
  • growing participation of generic drug manufacturers


  • Frequently Asked Questions (FAQ) :


    Myelodysplastic Syndrome (MDS) drugs market would record a CAGR of 10.1% during the forecast period of 2019-2025.

    Myelodysplastic Syndrome (MDS) drugs market had a valuation of USD 1581.59 million in 2018.

    The risk of infection with blood transfusion and chemotherapy’s side-effects can hold back the growth of the Myelodysplastic Syndrome (MDS) drugs market.

    Myelodysplastic Syndrome (MDS) drugs market report includes a discussion of oral, parenteral, and others.

    The Americas would hold the Myelodysplastic Syndrome (MDS) drugs market lead.

    Table of Contents

    Chapter 1. Executive Summary

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.3 Assumptions

    2.4 Limitations

    Chapter 3. Research Methodology

    3.1 Research Process

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    3.5 Forecast Model

    Chapter 4. Market Dynamics

    4.1 Overview

    4.2 Drivers

    4.3 Restraints

    4.4 Opportunities

    4.5 Pipeline Analysis

    4.5 Macroeconomic Indicators

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Opportunities

    Chapter 6. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type

    6.1 Overview

    6.2 Chemotherapy

    6.2.1 Hypomethylating Drugs

    6.2.1.1 Azacitidine

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.1.2 Decitabine

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.2 Conventional Drugs

    6.2.2.1 Cytarabine

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.2.2 Daunorubicin

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.2.3 Idarubicin

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3 Immunomodulatory Drugs

    6.3.1 Lenalidomide

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3.2 Thalidomide

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027


    Chapter 7. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type of Syndrome

    7.1 Overview

    7.2 Refractory Anemia

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3 Refractory Anemia with Ringed Sideroblasts

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4 Refractory Anemia with Excess Blasts

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.5 Refractory Cytopenia with Multilineage Dysplasia

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.6 Other

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 8. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Route of Administration

    8.1 Overview

    8.2 Oral

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3 Parenteral

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 9. Global Myelodysplastic Syndrome (MDS) Drugs Market, by End User

    9.1 Overview

    9.2 Hospitals

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.3 Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.4 Ambulatory Surgical Centers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.5 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 10. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Region

    10.1 Overview

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 Latin America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Overview

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12 Company Profiles

    12.1 BluePoint Laboratories

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.1.6 Key Strategies

    12.2 Celgene Corporation

    12.3 Cipla USA Inc

    12.4 Dr. Reddy's Laboratories Inc

    12.5 Fosun Pharma Industrial Pte. Ltd.

    12.6 Hikma Pharmaceuticals PLC

    12.7 Jazz Pharmaceuticals, Inc.

    12.8 Johnson & Johnson

    12.9 Lupin Ltd

    12.10 Otsuka America Pharmaceutical, Inc

    12.11 Pfizer

    12.12 Sandoz

    12.13 Shilpa Medicare Limited

    12.14 Sun Pharmaceutical Industries, Inc

    12.15 Teva Pharmaceutical Industries Ltd

    12.16 Others

    Chapter 13 Appendix


    LIST OF TABLES

    TABLE 1. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SYNOPSIS, 2020-2027

    TABLE 2. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)

    TABLE 3. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 4. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 5. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 6. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 7. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 8. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 9. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 10. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 11. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 12. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 13. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 14. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 15. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 16. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 17. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 18. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 19. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 20. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 21. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 22. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 23. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 24. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 25. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 26. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 27. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 28. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 29. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 30. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 31. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 32. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 33. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 34. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 35. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 36. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 37. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 38. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 39. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 40. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 41. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

    TABLE 42. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 43. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

    LIST OF FIGURES

    FIGURE 1. RESEARCH PROCESS

    FIGURE 2. SEGMENTATION FOR GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET

    FIGURE 3. MARKET DYNAMICS FOR GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET

    FIGURE 4. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY TYPE, 2020

    FIGURE 5. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY TYPE OF SYNDROME, 2020

    FIGURE 6. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION

    FIGURE 7. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY END USER, 2020

    FIGURE 8. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY REGION, 2020

    FIGURE 9. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY COUNTRY, 2020

    FIGURE 10. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY COUNTRY, 2020

    FIGURE 11. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY COUNTRY, 2020

    FIGURE 12. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY REGION, 2020

    FIGURE 13. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 14. BLUEPOINT LABORATORIES: KEY FINANCIALS

    FIGURE 15. BLUEPOINT LABORATORIES: SEGMENTAL REVENUE

    FIGURE 16. BLUEPOINT LABORATORIES: GEOGRAPHICAL REVENUE

    FIGURE 17. CELGENE CORPORATION: KEY FINANCIALS

    FIGURE 18. CELGENE CORPORATION: SEGMENTAL REVENUE

    FIGURE 19. CELGENE CORPORATION: GEOGRAPHICAL REVENUE

    FIGURE 20. CELGENE EUROPE LIMITED: KEY FINANCIALS

    FIGURE 21. CELGENE EUROPE LIMITED: SEGMENTAL REVENUE

    FIGURE 22. CELGENE EUROPE LIMITED: GEOGRAPHICAL REVENUE

    FIGURE 23. CIPLA USA INC: KEY FINANCIALS

    FIGURE 24. CIPLA USA INC: SEGMENTAL REVENUE

    FIGURE 25. CIPLA USA INC: GEOGRAPHICAL REVENUE

    FIGURE 26. DR. REDDY’S LABORATORIES INC: KEY FINANCIALS

    FIGURE 27. DR. REDDY’S LABORATORIES INC: SEGMENTAL REVENUE

    FIGURE 28. DR. REDDY’S LABORATORIES INC: GEOGRAPHICAL REVENUE

    FIGURE 29. FOSUN PHARMA INDUSTRIAL PTE. LTD.: KEY FINANCIALS

    FIGURE 30. FOSUN PHARMA INDUSTRIAL PTE. LTD.: SEGMENTAL REVENUE

    FIGURE 31. FOSUN PHARMA INDUSTRIAL PTE. LTD.: GEOGRAPHICAL REVENUE

    FIGURE 32. HIKMA PHARMACEUTICALS PLC: KEY FINANCIALS

    FIGURE 33. PHARMACEUTICALS PLC: SEGMENTAL REVENUE

    FIGURE 34. HIKMA PHARMACEUTICALS PLC: GEOGRAPHICAL REVENUE

    FIGURE 35. JAZZ PHARMACEUTICALS, INC: KEY FINANCIALS

    FIGURE 36. JAZZ PHARMACEUTICALS, INC: SEGMENTAL REVENUE

    FIGURE 37. JAZZ PHARMACEUTICALS, INC: GEOGRAPHICAL REVENUE

    FIGURE 38. JOHNSON & JOHNSON: KEY FINANCIALS

    FIGURE 39. JOHNSON & JOHNSON: SEGMENTAL REVENUE

    FIGURE 40. JOHNSON & JOHNSON: GEOGRAPHICAL REVENUE

    FIGURE 41. LUPIN LTD: KEY FINANCIALS

    FIGURE 42. LUPIN LTD: SEGMENTAL REVENUE

    FIGURE 43. LUPIN LTD: GEOGRAPHICAL REVENUE

    FIGURE 44. OTSUKA AMERICA PHARMACEUTICAL, INC: KEY FINANCIALS

    FIGURE 45. OTSUKA AMERICA PHARMACEUTICAL, INC: SEGMENTAL REVENUE

    FIGURE 46. OTSUKA AMERICA PHARMACEUTICAL, INC: GEOGRAPHICAL REVENUE

    FIGURE 47. PFIZER: KEY FINANCIALS

    FIGURE 48. PFIZER: SEGMENTAL REVENUE

    FIGURE 49. PFIZER: GEOGRAPHICAL REVENUE

    FIGURE 50. SANDOZ: KEY FINANCIALS

    FIGURE 51. SANDOZ: SEGMENTAL REVENUE

    FIGURE 52. SANDOZ: GEOGRAPHICAL REVENUE

    FIGURE 53. SHILPA MEDICARE LIMITED: KEY FINANCIALS

    FIGURE 54. SHILPA MEDICARE LIMITED: SEGMENTAL REVENUE

    FIGURE 55. SHILPA MEDICARE LIMITED: GEOGRAPHICAL REVENUE

    FIGURE 56. SUN PHARMACEUTICAL INDUSTRIES, INC: KEY FINANCIALS

    FIGURE 57. SUN PHARMACEUTICAL INDUSTRIES, INC: SEGMENTAL REVENUE

    FIGURE 58. SUN PHARMACEUTICAL INDUSTRIES, INC: GEOGRAPHICAL REVENUE

    FIGURE 59. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS

    FIGURE 60. TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE

    FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL REVENUE




    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.